0001193125-14-284023.txt : 20140911 0001193125-14-284023.hdr.sgml : 20140911 20140729115053 ACCESSION NUMBER: 0001193125-14-284023 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20140729 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vascular Biogenics Ltd. CENTRAL INDEX KEY: 0001603207 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 6 JONATHAN NETANYAHU ST. CITY: OR YEHUDA STATE: L3 ZIP: 60376 BUSINESS PHONE: 972-3-6346450 MAIL ADDRESS: STREET 1: 6 JONATHAN NETANYAHU ST. CITY: OR YEHUDA STATE: L3 ZIP: 60376 CORRESP 1 filename1.htm CORRESP

Vascular Biogenics Ltd.

6 Jonathan Netanyahu St.

Or Yehuda

Israel 60376

VIA EDGAR

July 29, 2014

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549-4720

Attention: Pamela Long

 

Re: Vascular Biogenics Ltd.
     Acceleration Request for Registration Statement on Form F-1
     File No. 333-196584

 

Dear Ms. Long:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Vascular Biogenics Ltd. (the “Company”) hereby requests that the effective date and time of the above-referenced registration statement (the “Registration Statement”) be accelerated to July 30, 2014, at 4:00 p.m., Eastern Time, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission (the “Commission”). In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP, by calling Lawrence S. Wittenberg at (617) 570-1035. We also respectfully request that a copy of the written order from the Commission verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Lawrence S. Wittenberg, by facsimile to (617) 523-1231.

In connection with the foregoing, the Company hereby acknowledges the following:

 

  •   should the Commission or the staff of the Commission, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;

 

  •   the action of the Commission or the staff of the Commission, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and

 

  •   the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Under separate cover, Deutsche Bank Securities Inc. and Wells Fargo Securities, LLC, as representatives of the underwriters, will send the Commission a letter joining in this request for acceleration of the effective date. The representatives will also provide you with information with respect to clearance from the Financial Industry Regulatory Authority prior to the effective date.

If you have any questions regarding this request, please contact Lawrence S. Wittenberg of Goodwin Procter LLP at (617) 570-1035.

 

Sincerely,

 

VASCULAR BIOGENICS LTD.

/s/ Amos Ron

Amos Ron

Chief Financial Officer

 

cc: Dror Harats, Vascular Biogenics Ltd.

Mitchell S. Bloom, Goodwin Procter LLP

Lawrence S. Wittenberg, Goodwin Procter LLP

Yuval Horn, Horn & Co, Law Offices

Keren Kanir, Horn & Co, Law Offices

Brent B. Siler, Cooley LLP

Darren K. DeStefano, Cooley LLP

Chaim Friedland, Gornitzky & Co.

Ari Fried, Gornitzky & Co.